Search Menu

PDN Training Workshop

Feb 27 – Mar 1, 2019 (Athens, Greece)“How to Make Preclinical Research Robust”2nd Preclinical Data Network Training Workshop for Young ScientistsCoordinators (Europe): Anton Bespalov (PAASP), Thomas Steckler (Janssen)Coordinators (North America): Magali Haas, Patricia Kabitzke, Chantelle Ferland-Beckham (Cohen Veterans Bioscience)Local organizers: Christina Dalla, Nikolaos Kokras (National and Kapodistrian …

Read more

PAASP partner became TÜV-certified ‘Qualitätsbeauftragter, -manager and -auditor’

PAASP partner Björn Gerlach undertook a three-month course focusing on classical quality management systems, like ISO9001 and EFQM. After passing written and oral examinations, Björn became a TÜV-Rhineland certified quality manager (“Qualitätsbeauftragter, -manager and -auditor”).This knowledge will contribute to PAASP’s mission of enhancing quality in biomedical …

Read more

Re-evaluation of failed drugs and targets using contemporary knowledge, methodology and tools

Co-authored by PAASP’s managing partner, Anton Bespalov, the correspondence article ‘Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets’ was published last week in Nature Reviews Drug Discovery. Here, the authors discuss the great importance of 1. Data robustness, …

Read more

Development of an information sharing platform – Pharma shares unpublished results

F1000 Research has published an article entitled “In search of the mechanisms of ketamine’s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis” co-authored by PAASP’s managing partner Anton Bespalov, together with colleagues from AbbVie, Servier, Pfizer and Alkermes. Independently of each other, …

Read more

Scroll Up